Intracellular NAD⁺ depletion enhances bortezomib-induced anti-myeloma activity.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Blood

• Publication date

  2013-08-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1182/blood-2013-02-483511PMID 23823317PMCID PMC3744991
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Intracellular NAD+ depletion induces autophagic death in multiple myeloma cells

  2013cited by this paper
• The NAD metabolome — a key determinant of cancer cell biology

  2012cited by this paper
• Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition.

  2012cited by this paper
• Novel agents improve survival of transplant patients with multiple myeloma including those with high-risk disease defined by early relapse (<12 months)

  2011cited by this paper
• Hallmarks of cancer: the next generation.

  2011cited by this paper
• Compromising the Unfolded Protein Response Induces Autophagy-Mediated Cell Death in Multiple Myeloma Cells

  2011cited by this paper
• Regulation of cancer cell metabolism

  2011cited by this paper
• Advances in the understanding of mechanisms and therapeutic use of bortezomib.

  2011cited by this paper
• Reciprocal Potentiation of the Antitumoral Activities of FK866, an Inhibitor of Nicotinamide Phosphoribosyltransferase, and Etoposide or Cisplatin in Neuroblastoma Cells

  2011cited by this paper
• The ubiquitin-proteasomal system is critical for multiple myeloma: implications in drug discovery.

  2011cited by this paper
• The NF-κB Inhibitor LC-1 Has Single Agent Activity in Multiple Myeloma Cells and Synergizes with Bortezomib

  2010cited by this paper
• Tipifarnib sensitizes cells to proteasome inhibition by blocking degradation of bortezomib-induced aggresomes.

  2010cited by this paper
• The secret life of NAD+: an old metabolite controlling new metabolic signaling pathways.

  2010cited by this paper
• Potent synergistic interaction between the Nampt inhibitor APO866 and the apoptosis activator TRAIL in human leukemia cells.

  2010cited by this paper
• The NAD biosynthesis inhibitor APO866 has potent antitumor activity against hematologic malignancies.

  2009cited by this paper
• APO866 activity in hematologic malignancies: a preclinical in vitro study.

  2009cited by this paper
• Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation

  2009cited by this paper
• Catastrophic NAD+ Depletion in Activated T Lymphocytes through Nampt Inhibition Reduces Demyelination and Disability in EAE

  2009cited by this paper
• The Small Molecule GMX1778 Is a Potent Inhibitor of NAD+ Biosynthesis: Strategy for Enhanced Therapy in Nicotinic Acid Phosphoribosyltransferase 1-Deficient Tumors

  2009cited by this paper
• Multiple myeloma

  2009cited by this paper
• Improved survival in multiple myeloma and the impact of novel therapies.

  2008cited by this paper
• The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor

  2008cited by this paper
• NAD depletion by FK866 induces autophagy

  2008cited by this paper
• Bortezomib-Resistant Nuclear Factor-κB Activity in Multiple Myeloma Cells

  2008cited by this paper
• Nutrient-sensitive mitochondrial NAD+ levels dictate cell survival.

  2007cited by this paper
• Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets

  2007cited by this paper
• Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells.

  2006cited by this paper
• Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib.

  2006cited by this paper
• Chemopotentiating effects of a novel NAD biosynthesis inhibitor, FK866, in combination with antineoplastic agents.

  2006cited by this paper
• Metabolic Signatures Associated with a NAD Synthesis Inhibitor–Induced Tumor Apoptosis Identified by 1H-Decoupled-31P Magnetic Resonance Spectroscopy

  2005cited by this paper
• A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib.

  2005cited by this paper
• Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma.

  2005cited by this paper
• Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma.

  2005cited by this paper
• Gene Expression Profile Associated with Response to Doxorubicin-Based Therapy in Breast Cancer

  2005cited by this paper
• The new life of a centenarian: signalling functions of NAD(P).

  2004cited by this paper
• FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis.

  2003cited by this paper
• A phase 2 study of bortezomib in relapsed, refractory myeloma.

  2003cited by this paper
• The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.

  2001cited by this paper
• Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration.

  2001cited by this paper
• Proteasome inhibition measurements: clinical application.

  2000cited by this paper
• Role of NF-kappaB in the rescue of multiple myeloma cells from glucocorticoid-induced apoptosis by bcl-2.

  1999cited by this paper
• Identification of the yeast 20S proteasome catalytic centers and subunit interactions required for active-site formation.

  1997cited by this paper
• The Active Sites of the Eukaryotic 20 S Proteasome and Their Involvement in Subunit Precursor Processing*

  1997cited by this paper
• Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B.

  1996cited by this paper
• Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma.

  1991cited by this paper
• Abnormally high expression of proteasomes in human leukemic cells.

  1990cited by this paper
• Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.

  1984cited by this paper
• Multiple myeloma.

  1948cited by this paper

• A rabbit anti-human CD38 antibody for eliminating daratumumab and isatuximab interference in immunohematology testing.

  2026cites this paper
• Unraveling Obesity and Multiple Myeloma: Insights from Epidemiology and Molecular Mechanisms

  2025cites this paper
• NAMPT Modulates Gemcitabine Resistance in Pancreatic Cancer via the p53 Signaling Pathway.

  2025cites this paper
• Metronomic chemotherapy in hematology: lessons from preclinical and clinical studies to build a solid rationale for future schedules.

  2024cites this paper
• Regulation of ubiquitin-proteasome system and its relative pathways in pancreatic adenocarcinoma

  2024cites this paper
• NAD+ metabolism restriction boosts high-dose melphalan efficacy in patients with multiple myeloma

  2024cites this paper
• CD38-Induced Metabolic Dysfunction Primes Multiple Myeloma Cells for NAD+-Lowering Agents

  2023cites this paper
• Obesity as a risk factor for multiple myeloma: insight on the role of adipokines

  2023cites this paper
• Discovery of a novel NAMPT inhibitor that selectively targets NAPRT-deficient EMT-subtype cancer cells and alleviates chemotherapy-induced peripheral neuropathy

  2023cites this paper
• Interplay between proteasome function and inflammatory responses in e-cig vapor condensate-challenged lung epithelial cells

  2023cites this paper
• Anticancer Activities of Novel Nicotinamide Phosphoribosyltransferase Inhibitors in Hematological Malignancies

  2023cites this paper
• NAD/NAMPT and mTOR Pathways in Melanoma: Drivers of Drug Resistance and Prospective Therapeutic Targets

  2022cites this paper
• Cellular and molecular insights into the roles of visfatin in breast cancer cells plasticity programs.

  2022cites this paper
• Updated Functional Roles of NAMPT in Carcinogenesis and Therapeutic Niches

  2022cites this paper
• Race for the Cure: From the Oldest to the Newest Monoclonal Antibodies for Multiple Myeloma Treatment

  2022cites this paper
• NAMPT: a critical driver and therapeutic target for cancer.

  2022cites this paper
• secDrug: a pipeline to discover novel drug combinations to kill drug-resistant multiple myeloma cells using a greedy set cover algorithm and single-cell multi-omics

  2022cites this paper
• Importance of circulating adipocytokines in multiple myeloma: a systematic review and meta-analysis based on case-control studies

  2022cites this paper
• Daratumumab combined with dexamethasone and lenalidomide or bortezomib in relapsed/refractory multiple myeloma (RRMM) patients: Report from the multiple myeloma GIMEMA Lazio group

  2022cites this paper
• NAD+ depletion enhances reovirus-induced oncolysis in multiple myeloma

  2022cites this paper
• Review of various NAMPT inhibitors for the treatment of cancer

  2022cites this paper
• Daporinad in Vitro Metabolite Profiling via Rat, Dog, Monkey and Human Live Microsomes by Liquid Chromatography-Quadrupole/Orbitrap Mass Spectrometry.

  2021cites this paper
• Advances in NAD-Lowering Agents for Cancer Treatment

  2021cites this paper
• The Landscape of Signaling Pathways and Proteasome Inhibitors Combinations in Multiple Myeloma

  2021cites this paper
• An evaluation of isatuximab, pomalidomide and dexamethasone for adult patients with relapsed and refractory multiple myeloma

  2021cites this paper
• The Modern Age of Monoclonal Antibodies: The Revolution of Daratumumab

  2021cites this paper
• Targeting Reactive Oxygen Species Metabolism to Induce Myeloma Cell Death

  2021cites this paper
• Amino acid depletion triggered by ʟ-asparaginase sensitizes MM cells to carfilzomib by inducing mitochondria ROS-mediated cell death.

  2020cites this paper
• Recent Advances in NAMPT Inhibitors: A Novel Immunotherapic Strategy

  2020cites this paper
• Mitochondrial Functions, Energy Metabolism and Protein Glycosylation are Interconnected Processes Mediating Resistance to Bortezomib in Multiple Myeloma Cells

  2020cites this paper
• NAD- and NADPH-Contributing Enzymes as Therapeutic Targets in Cancer: An Overview

  2020cites this paper
• Cross-talk between redox signalling and protein aggregation

  2020cites this paper
• Prognostic value of visfatin in various human malignancies: A systematic review and meta-analysis.

  2020cites this paper
• Daratumumab in multiple myeloma

  2019cites this paper
• Subcellular compartmentalization of NAD+ and its role in cancer: A sereNADe of metabolic melodies.

  2019cites this paper
• Wild-Type IDH Enzymes as Actionable Targets for Cancer Therapy

  2019cites this paper
• NAMPT as a Dedifferentiation-Inducer Gene: NAD+ as Core Axis for Glioma Cancer Stem-Like Cells Maintenance

  2019cites this paper
• The role of visfatin in cancer proliferation, angiogenesis, metastasis, drug resistance and clinical prognosis

  2019cites this paper
• IDH2 inhibition enhances proteasome inhibitor responsiveness in hematological malignancies.

  2019cites this paper
• CMAR_A_199597 3481..3491

  2019cites this paper
• A metabolic switch in proteasome inhibitor-resistant multiple myeloma ensures higher mitochondrial metabolism, protein folding and sphingomyelin synthesis

  2019cites this paper
• Therapeutic Monoclonal Antibodies and Antibody Products: Current Practices and Development in Multiple Myeloma

  2019cites this paper
• Vincristine and bortezomib use distinct upstream mechanisms to activate a common SARM1-dependent axon degeneration program.

  2019cites this paper
• CD38: A Target for Immunotherapeutic Approaches in Multiple Myeloma

  2018cites this paper
• Cancer cell metabolic plasticity allows resistance to NAMPT inhibition but invariably induces dependence on LDHA

  2018cites this paper
• CD38 antibodies in multiple myeloma: back to the future.

  2018cites this paper
• Adipokines, adiposity, and bone marrow adipocytes: Dangerous accomplices in multiple myeloma

  2018cites this paper
• Redox regulation of proteasome function

  2017cites this paper
• FK866 attenuates acute hepatic failure through c-jun-N-terminal kinase (JNK)-dependent autophagy

  2017cites this paper
• Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma

  2017cites this paper
• Inhibition of nicotinamide phosphoribosyltransferase and depletion of nicotinamide adenine dinucleotide contribute to arsenic trioxide suppression of oral squamous cell carcinoma

  2017cites this paper
• Caracterización del gen Nampt en el proceso de patogénesis tumoral, valoración diagnóstica, pronóstica y como diana terapeútica.

  2017cites this paper
• Depletion of SIRT6 enzymatic activity increases acute myeloid leukemia cells’ vulnerability to DNA-damaging agents

  2017cites this paper
• The metabolomic signature of hematologic malignancies.

  2016cites this paper
• Nicotinamide phosphoribosyltransferase (Nampt) in carcinogenesis: new clinical opportunities

  2016cites this paper
• Autophagy is associated with cucurbitacin D-induced apoptosis in human T cell leukemia cells

  2016cites this paper
• Strong immunoexpression of dickkopf-1 is associated with response to bortezomib in multiple myeloma

  2016cites this paper
• The iron chelator deferasirox induces apoptosis by targeting oncogenic Pyk2/β-catenin signaling in human multiple myeloma

  2016cites this paper
• NAMPT and NAMPT-controlled NAD Metabolism in Vascular Repair

  2016cites this paper
• Pharmacogenomics and chemical library screens reveal a novel SCFSKP2 inhibitor that overcomes Bortezomib resistance in multiple myeloma

  2016cites this paper
• Exploiting tumor vulnerabilities: NAD+-depleting agents combined with anti-tumor drugs as innovative strategy to treat hematological malignancies

  2016cites this paper
• Mechanism of action of bortezomib in multiple myeloma therapy

  2016cites this paper
• NAD+ salvage pathway in cancer metabolism and therapy.

  2016cites this paper
• Endoplasmic-reticulum stress pathway-associated mechanisms of action of proteasome inhibitors in multiple myeloma

  2016cites this paper
• Dual NAMPT and BTK Targeting Leads to Synergistic Killing of Waldenström Macroglobulinemia Cells Regardless of MYD88 and CXCR4 Somatic Mutation Status

  2016influential citation
• Molecular Effects of the Nampt Inhibitor FK866 on Leukemia Cells

  2016cites this paper
• Nicotinamide Phosphoribosyl Transferase and Cancer: A Molecular Nutrition Link

  2016cites this paper
• Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) as a therapeutic strategy in cancer.

  2015cites this paper
• New strategies to maximize therapeutic opportunities for NAMPT inhibitors in oncology

  2015cites this paper
• Secretion of One Adipokine Nampt/Visfatin Suppresses the Inflammatory Stress-Induced NF-κB Activity and Affects Nampt-Dependent Cell Viability in Huh-7 Cells

  2015cites this paper
• APO866 Increases Antitumor Activity of Cyclosporin-A by Inducing Mitochondrial and Endoplasmic Reticulum Stress in Leukemia Cells

  2015influential citation
• Research into cancer metabolomics: Towards a clinical metamorphosis.

  2015cites this paper
• Combinative effects of β-Lapachone and APO866 on pancreatic cancer cell death through reactive oxygen species production and PARP-1 activation.

  2015cites this paper
• NAD+-Metabolizing Ectoenzymes in Remodeling Tumor–Host Interactions: The Human Myeloma Model

  2015cites this paper
• Bortezomib and Arsenic Trioxide Activity on a Myelodysplastic Cell Line (P39): A Gene Expression Study

  2015cites this paper
• Intracellular nicotinamide adenine dinucleotide promotes TNF-induced necroptosis in a sirtuin-dependent manner

  2015cites this paper
• The Keap1-Nrf2-antioxidant response element pathway: a review of its regulation by melatonin and the proteasome.

  2015cites this paper
• EIF2A-dependent translational arrest protects leukemia cells from the energetic stress induced by NAMPT inhibition

  2015cites this paper
• The NAMPT-mediated NAD salvage pathway in cancer cell metabolism and its regulation by resveratrol

  2015cites this paper
• Lower expression of activating transcription factors 3 and 4 correlates with shorter progression-free survival in multiple myeloma patients receiving bortezomib plus dexamethasone therapy

  2015cites this paper
• The NAD+ salvage pathway modulates cancer cell viability via p73

  2015cites this paper
• VISFATIN PROMOTES FOAM CELL FORMATION BY DYSREGULATING CD36, SRA, ABCA1, AND ABCG1 EXPRESSION IN RAW264.7 MACROPHAGES

  2015cites this paper
• Role of CIP2A in the antitumor effect of bortezomib in colon cancer.

  2014cites this paper
• Cancer Therapy: Preclinical On-Target Effect of FK866, a Nicotinamide Phosphoribosyl Transferase Inhibitor, by Apoptosis-Mediated Death in Chronic Lymphocytic Leukemia Cells

  2014cites this paper
• Cancer Therapy : Preclinical On-Target Effect of FK 866 , a Nicotinamide Phosphoribosyl Transferase Inhibitor , by Apoptosis-Mediated Death in Chronic Lymphocytic Leukemia Cells

  2014cites this paper
• On-Target Effect of FK866, a Nicotinamide Phosphoribosyl Transferase Inhibitor, by Apoptosis-Mediated Death in Chronic Lymphocytic Leukemia Cells

  2014cites this paper
• Resveratrol differentially regulates NAMPT and SIRT1 in hepatocarcinoma cells and primary human hepatocytes

  2014cites this paper
• Resistance to Proteasome Inhibitors in Multiple Myeloma

  2014cites this paper
• Resveratrol Differentially Regulates NAMPT and SIRT1 in Hepatocarcinoma Cells and Primary Human Hepatocytes

  2014cites this paper
• Nicotinamide phosphoribosyltransferase (NAMPT) activity is essential for survival of resting lymphocytes

  2014cites this paper
• Understanding Tumour Metabolic Reprogramming with Metabolomics

  2013cites this paper
• MULTIPLE NUCLEAR RECEPTORS AND CIRCADIAN RHYTHM FACTORS MODULATE HUMAN CYTOMEGALOVIRUS REPLICATION

  2013cites this paper